Active Infection & Immunity Lungs & Breathing

RadioTB trial: Optimal management of radiographically apparent, bacteriologically negative TB identified through active case finding

In plain English

AI plain-English summary

Millions of people each year now receive chest X-rays screened by computer software to find undiagnosed tuberculosis, but roughly 5–7% of those without prior TB show suspicious lung abnormalities while testing negative for the bacteria—and about 10% of them will develop infectious TB within a year. This group sits in a clinical blind spot. No one knows the best way to manage them: whether to treat with standard TB drugs, and if so, for how long. Current practice varies wildly, and the opportunity to prevent transmission and permanent lung damage is routinely missed. The last randomised trial in this population was conducted over 30 years ago. The RadioTB trial will run across South Africa, Zimbabwe, and Pakistan, embedded in existing screening programmes. It uses a pragmatic duration-response design to test the shortest standard regimen that stops progression. Alongside the trial, researchers will evaluate novel diagnostics, model transmission effects, and assess cost-effectiveness of different strategies. If successful, the trial could provide the first robust evidence in decades to guide global policy—turning a neglected, high-risk group into a target for early, efficient intervention that reduces TB spread and preserves lung health.

View original technical description
Chest X-ray (CXR) screening using computer-aided detection (CAD) software is the optimal approach to identify those with undiagnosed tuberculosis (TB) in communities and is being rapidly scaled-up globally with millions screened each year. Approximately 5-7% of people without previous TB history have a CXR suggestive of TB but no bacteriological confirmation and are at high-risk of progressing to develop infectious TB (approximately 10%/year). The optimal diagnostic and treatment approach for this group is unclear due to insufficient evidence and in practice is highly variable. Frequently the opportunity for early intervention to prevent transmission and minimise lung damage is missed. Our overall goal is to provide strong evidence to guide policy for programmatic management and to advance understanding about this early TB state. We will undertake the first randomised clinical trial (RCT) in this population for over 30 years, using a pragmatic approach and innovative duration-response design to determine the shortest duration of the standard regimen required to prevent progression. The trial will be undertaken in South Africa, Zimbabwe and Pakistan alongside programmatic screening, providing efficiency. In addition, we will evaluate the potential of novel diagnostic approaches, model the impact on transmission, and evaluate the cost- effectiveness of the different management strategies.

View the original record at the funder ↗

Researchers

Edson Marambire (EPMC Awardee)Tom Boyles (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

A randomised controlled trial (RCT) to evaluate a scalable active case finding primary care-based intervention for tuberculosis using a point-of-care
MICA: Radio+ TB trial development: Determining the optimal regimen for bacteriologically negative, radiographically apparent TB diagnosed usingnewtest
Impact of a novel molecular TB diagnostic system on clinical outcomes of multidrug-resistant TB in rural South Africa.
The use of modern molecular tools to understand and intervene in the spread of multidrug-resistant tuberculosis in rural South Africa.
PRecision biomArker Guided MAnagement of TuberculosIs Contacts (PRAGMATIC)

Original classification

Discretionary Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.